Several studies have shown that patients with HR+/HER2+ breast cancer are more likely to exhibit resistance to anti-HER2 and endocrine therapy and have a worse prognosis than patients with hormone receptor-positive HER2-negative (HR+/HER2-) disease. This evidence concerns the gene NR4A1 and breast cancer.